EP 20: I Want to Die Fast, in a Young Body, at an Old Age — Regan Archibald on Peptides, Stem Cells, and the End of Slow Decline

Most people don't extend their life. They extend their dying. The final decade becomes the worst one — chronic disease dragged out for years, mobility gone, the body outliving the ability to enjoy being in it. Regan Archibald has a different goal, and he states it plainly: he wants to die fast, in a young body, at an old age. He's aiming for 222.

Regan is the founder of Ageless Future and one of the most credentialed voices in peptide therapy working today. He's a member of Da Vinci 50 — fifty of the world's leading longevity researchers and clinicians who meet three times a year to compare notes on what's actually working — and he holds a patent on stacking and prescribing peptides based on blood labs. Over 22 years and more than 72,000 patients through his clinics, he's built a practice around a question conventional medicine rarely asks: not what's wrong, but what triggered it in the first place.

He came to it the hard way. As a medical student he got so sick he couldn't run a mile without pain, couldn't sleep despite constant exhaustion, and had brain fog so severe he could only study between 7pm and 9pm — recording lectures on a cassette player because he couldn't process them live. Five doctors ran his labs and told him everything looked normal. Their best advice was to take fewer courses. The doctor who finally figured it out found Hashimoto's, then traced it back to formaldehyde exposure in the anatomy lab and years of Roundup on the family cattle ranch in Idaho.

This episode is dense with things you can act on.

Regan walks through the GLP-1 landscape with a level of specificity you won't get from a headline. Why Ozempic is effective but harsh — the delayed gastric emptying, the digestive problems, the muscle mass lost alongside the fat, and anhedonia, the flattening of pleasure that's now showing up in users. Why tirzepatide has a better safety profile, and the striking study where two groups each lost 20 pounds — one through diet and exercise, one on tirzepatide — and the medicated group came out with better kidney function, better cardiovascular markers, better blood sugar and better cognition. Then retatrutide, which he calls possibly the biggest medical breakthrough of our lifetime: three peptides stacked in a way that cancels out each one's side effects, with trial participants on the highest dose averaging 71 pounds of weight loss.

There's a properly useful stretch on what to actually measure. Why VO2 max may be the single most predictive marker you can track — one study found elite VO2 max cut all-cause mortality risk by over 400 percent. Why he's more skeptical of sleep scores and HRV than most: across 72,000 patients, people with high heart rate variability aren't reliably healthier, and people getting more deep and REM sleep don't reliably feel better. Baselines and trends are useful. Comparing your numbers to someone else's is where people go wrong, because every biology is different.

And a warning worth hearing before you buy anything: purity and sterility are not the same thing. When a listener described a bad reaction to a peptide, Regan's first question was where it came from — because contamination from a non-503A compounding pharmacy explains a lot of the reactions people blame on the peptide itself.

The conversation ranges wider than the science. George opens with a story about taking a patient with late-stage Parkinson's into the ocean because she didn't feel safe getting off the bank alone — and what it looked like when she got there. There's the mastermind question George put to three heavy hitters (what business will still exist in seven years?) and the fact that all three landed on human-centric, off-the-computer industries. Regan cites the Harvard finding that loneliness shortens your life by seven years. And there's a candid exchange on patents, IP, and whether locking up naturally occurring compounds helps or hinders the people who need them.

The line that anchors the whole thing: